InsidersTradesSigma
NRX Pharmaceuticals, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the NRX Pharmaceuticals, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, NRX Pharmaceuticals, Inc. has published 51 public disclosures. The latest transaction was reported on 18 December 2024 (Acquisition). Among the most active insiders: Javitt Daniel C.. The full history is accessible without an account.
51
Insider Decl.
0
Thresholds
€6m
14 ops.
Buy Volume
€2m
12 ops.
Sell Volume
52Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 18 December 2024
Declarations51 total
40,000 shares@ US$1.170.7% of flowCommon StockSEC:0001415889-24-029694:0
Ideal exit: 13 Sept 2025 (T+270)
35,000 shares@ US$0.3199100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-23-013139:0
Ideal exit: 26 May 2024 (T+270)
70,000 shares@ US$0.28753.2% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-23-013137:0
Ideal exit: 26 May 2024 (T+270)
100,000 shares@ US$0.330.5% of flowCommon StockSEC:0001104659-23-094815:0
Ideal exit: 19 May 2024 (T+270)
200,000 shares@ US$0.3221.0% of flowCommon StockSEC:0001104659-23-094406:0
Ideal exit: 18 May 2024 (T+270)
50,000 shares@ US$1.17100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012654:0
Ideal exit: 12 Sept 2023 (T+270)
30,000 shares@ US$1.1062.3% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012652:0
Ideal exit: 12 Sept 2023 (T+270)
8,716 shares@ US$1.1218.8% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012650:0
Ideal exit: 22 Aug 2023 (T+270)
400,000 shares@ US$1.006.4% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012324:0
13,730 shares@ US$1.50411.8% of flowcommon stockSEC:0000880984-22-000017:0
2,500 shares@ US$1.25100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-011810:0
Ideal exit: 25 Aug 2023 (T+270)
8,716 shares@ US$1.1218.8% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-011778:0
Ideal exit: 22 Aug 2023 (T+270)
287,812 shares@ US$0.9948.4% of flowCommon StockSEC:0000950142-22-003250:0
Ideal exit: 13 Aug 2023 (T+270)
287,812 shares@ US$0.9948.4% of flowCommon StockSEC:0000950142-22-003233:0
Ideal exit: 13 Aug 2023 (T+270)
133,719 shares@ US$1.0211.6% of flowcommon stockSEC:0000880984-22-000015:0
49,200 shares@ US$1.00634.3% of flowcommon stockSEC:0000880984-22-000014:0
784,063 shares@ US$1.009468.4% of flowCommon StockSEC:0000880984-22-000009:0
2,000,000 shares0Common StockSEC:0000880984-22-000008:0
243,596 shares@ US$0.7024100.0% of flowCommon StockSEC:0000880984-22-000007:0
100,000 shares@ US$0.581.0% of flowCommon StockSEC:0000921895-22-001874:0
Ideal exit: 26 Feb 2023 (T+270)
100,000 shares@ US$58.0099.0% of flowCommon StockSEC:0000921895-22-001872:0
Ideal exit: 26 Feb 2023 (T+270)
63,710 shares@ US$0.2050.0% of flowCommon StockSEC:0000950142-21-003503:0
63,710 shares@ US$0.20100.0% of flowCommon StockSEC:0000950142-21-003503
434,594 sharesCommon StockSEC:0000950142-21-003505
18,300 shares@ US$2.22100.0% of flowCommon StockSEC:0000950142-21-003506
25 of 51 declarations
About NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market under ticker NRXPW. Headquartered in Wilmington, Delaware, United States, the company is focused on severe psychiatric and central nervous system disorders with significant unmet medical need. Its business model is built around clinical development, regulatory execution, and eventual commercialization of therapies aimed at patients with severe depression, bipolar depression with suicidal ideation, PTSD, and related neuropsychiatric conditions. NRx was founded around the premise of repurposing known molecules for high-value, high-need indications rather than relying solely on de novo drug discovery. That positioning has shaped the company into a specialist in interventional psychiatry. Its core programs center on NRX-100, a preservative-free intravenous ketamine product, and NRX-101, an oral combination therapy being developed for bipolar depression in patients with suicidal ideation and behavior. The company also references broader development efforts in PTSD and other severe mental health disorders. From a competitive standpoint, NRx remains a small-cap, development-stage company, which means it carries materially higher execution and regulatory risk than large-cap pharmaceutical peers. Its potential strategic advantage lies in its narrow therapeutic focus, the use of known pharmacology, and the targeting of clinically urgent patient segments where treatment options remain limited. Management has pursued multiple regulatory paths, including both ANDA and NDA strategies, to broaden the probability of eventual approval and commercialization. In parallel with its drug pipeline, NRx has launched HOPE Therapeutics, a subsidiary aimed at delivering integrated psychiatric care. That platform combines neuroplastic medications, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy, digital therapeutics, and medication management. This services-based layer could help the company build closer links with patients and prescribing physicians while creating a complementary commercial channel alongside its pharmaceutical pipeline. Recent company developments are highly relevant for investors. During 2025 and into early 2026, NRx reported regulatory progress with the FDA on NRX-100, including Fast Track designation and discussions intended to identify a path toward broader approval. The company also said it had refiled an ANDA for preservative-free ketamine and was targeting an NDA filing around June 2026. For French-speaking investors, NRx should therefore be viewed as a speculative NASDAQ-listed U.S. healthcare name with a strong regulatory catalyst profile and meaningful dependence on FDA outcomes.
